The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | ORCHESTRA: tumor debulking in metastatic colorectal cancer
Elske Gootjes, MD, Amsterdam University Medical Center, Amsterdam, Netherlands, gives insight on the randomized Phase III ORCHESTRA trial (NCT01792934) investigating palliative systemic therapy versus palliative systemic therapy plus tumor debulking in patients with multiorgan metastatic colorectal cancer. Results showed that the addition of tumor debulking to systemic therapy showed no improvement in overall survival (OS). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
